NCT00525564View on ClinicalTrials.gov

Effects of Salmeterol on Walking Capacity in Patients With COPD

PHASE4CompletedINTERVENTIONAL

Enrollment

28

Participants

Timeline

Start Date

May 31, 2006

Study Completion Date

October 31, 2006

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

Placebo

Placebo diskus inhalation powder

DRUG

Salmeterol diskus inhalation powder

50 micrograms twice a day

Trial Locations (1)

G1V 4G5

Hôpital Laval, Québec

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Laval University

OTHER

NCT00525564 - Effects of Salmeterol on Walking Capacity in Patients With COPD | Biotech Hunter | Biotech Hunter